Tuberculosis

Vitamin C Rapidly Kills Drug-resistant Tuberculosis Bacteria

alt

Vitamin C causes a chemical reaction that rapidly destroys Mycobacterium tuberculosis that is resistant to isoniazid and other drugs, researchers determined in a serendipitous discovery described in the May 21, 2013, edition of Nature Communications.

Catherine Vilchèze from Howard Hughes Medical Institute, William Jacobs from Albert Einstein College of Medicine, and colleagues found that vitamin C sterilized TB bacteria cultures by means of the Fenton reaction, or generation of reactive oxygen radicals.

The researchers suggested it may be beneficial to add vitamin C to anti-TB regimens, or the discovery could spur development of drugs that work by a similar mechanism.

"We don't know whether vitamin C will work in humans, but we now have a rational basis for doing a clinical trial," Jacobs said.

Below is an edited excerpt from a press release issued by Albert Einstein College of Medicine describing the study and its findings.

Study Finds Vitamin C Can Kill Drug-Resistant TB

May 21, 2013 -- In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis (TB) bacteria in laboratory culture. The finding suggests that vitamin C added to existing TB drugs could shorten TB therapy, and it highlights a new area for drug design. The study was published today in the online journal Nature Communications.

TB is caused by infection with the bacterium M. tuberculosis. In 2011, TB sickened some 8.7 million people and took some 1.4 million lives, according to the World Health Organization. Infections that fail to respond to TB drugs are a growing problem: About 650,000 people worldwide now have multi-drug-resistant TB (MDR-TB), 9 percent of whom have extensively drug-resistant TB (XDR-TB).TB is especially acute in low and middle income countries, which account for more than 95 percent of TB-related deaths, according to the World Health Organization.

The Einstein discovery arose during research into how TB bacteria become resistant to isoniazid, a potent first-line TB drug. The lead investigator and senior author of the study was William Jacobs, Jr. PhD, professor of microbiology and immunology and of genetics at Einstein. Dr. Jacobs is a Howard Hughes Medical Institute investigator and a recently elected member of the National Academy of Sciences.

Dr. Jacobs and his colleagues observed that isoniazid-resistant TB bacteria were deficient in a molecule called mycothiol. "We hypothesized that TB bacteria that can't make mycothiol might contain more cysteine, an amino acid," said Dr. Jacobs. "So, we predicted that if we added isoniazid and cysteine to isoniazid-sensitive M. tuberculosis in culture, the bacteria would develop resistance. Instead, we ended up killing off the culture -- something totally unexpected."

The Einstein team suspected that cysteine was helping to kill TB bacteria by acting as a "reducing agent" that triggers the production of reactive oxygen species (sometimes called free radicals), which can damage DNA.

"To test this hypothesis, we repeated the experiment using isoniazid and a different reducing agent -- vitamin C," said Dr. Jacobs. "The combination of isoniazid and vitamin C sterilized the M. tuberculosis culture. We were then amazed to discover that vitamin C by itself not only sterilized the drug-susceptible TB, but also sterilized MDR-TB and XDR-TB strains."

To justify testing vitamin C in a clinical trial, Dr. Jacobs needed to find the molecular mechanism by which vitamin C exerted its lethal effect. More research produced the answer: Vitamin C induced what is known as a Fenton reaction, causing iron to react with other molecules to create reactive oxygen species that kill the TB bacteria.

"We don't know whether vitamin C will work in humans, but we now have a rational basis for doing a clinical trial," said Dr. Jacobs. "It also helps that we know vitamin C is inexpensive, widely available and very safe to use. At the very least, this work shows us a new mechanism that we can exploit to attack TB."

The study was supported by a grant (AI26170) from National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
 
5/30/13

Reference

C Vilchèze, T Hartman, B Weinrick, and WR Jacobs. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nature Communications 4(188). May 21, 2013.

Other Source

Albert Einstein College of Medicine. Study Finds Vitamin C Can Kill Drug-Resistant TB. Press release. May 21, 2103.